β2肾上腺素能受体激动剂与拮抗剂使用与帕金森病风险
该研究基于丹麦全国健康登记数据,纳入2790例帕金森病患者和11160例对照,验证β2AR激动剂与拮抗剂分别与PD风险降低和升高的关联。结果显示长期β2AR激动剂使用与PD风险降低相关(OR 0.57),但短期使用同样相关,且COPD诊断及吸入药物也呈负相关,提示关联可能由吸烟间接介导。β2AR拮抗剂中仅普萘洛尔和美托洛尔与风险升高相关,且短期使用关联更强,提示反向因果。结论认为当前流行病学数据不支持β2AR药物与PD风险存在因果联系。
要点
- 长期β2AR激动剂使用与PD风险降低相关(OR 0.57,95%CI 0.40-0.82)。
- 短期β2AR激动剂使用同样与PD风险降低相关(OR 0.64,95%CI 0.42-0.98)。
- 仅普萘洛尔和美托洛尔与PD风险升高相关,短期使用关联更强,提示反向因果。
核心结论
- β2AR激动剂使用与PD风险降低相关,但可能由吸烟间接介导。
- β2AR拮抗剂与PD风险升高的关联提示反向因果,即PD症状触发处方。
- 当前流行病学数据不支持β2AR激动剂或拮抗剂与PD风险存在因果联系。
研究设计与样本
- 基于丹麦全国健康登记系统的病例对照研究,纳入2790例PD患者和11160例对照。
- 计算β2AR激动剂和拮抗剂使用时间与PD风险的比值比(OR)。
主要发现
- 长期β2AR激动剂使用与PD风险降低相关(OR 0.57,95%CI 0.40-0.82)。
- 短期β2AR激动剂使用同样与PD风险降低相关(OR 0.64,95%CI 0.42-0.98)。
- COPD诊断(OR 0.51,95%CI 0.37-0.69)、吸入糖皮质激素(OR 0.78,95%CI 0.59-1.02)或吸入抗胆碱能药(OR 0.41,95%CI 0.25-0.67)均与PD风险呈负相关。
- β2AR拮抗剂中仅普萘洛尔和美托洛尔与PD风险升高相关,且短期使用关联强于长期使用。
临床怎么用
- 临床不应因PD风险顾虑而改变β2AR激动剂或拮抗剂的处方决策。
- 对于使用普萘洛尔或美托洛尔的患者,PD风险升高可能反映反向因果,需注意PD症状的识别。
局限性
- 关联可能受吸烟等混杂因素影响,β2AR激动剂的保护作用可能由吸烟间接介导。
- β2AR拮抗剂的关联提示反向因果,不能排除PD早期症状影响药物使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To verify the previously reported association between long-term use of β2-adrenoreceptor (β2AR) agonist and antagonist with reduced and increased risk of Parkinson disease (PD), respectively. METHODS: We obtained odds ratios (ORs) associating time of β2AR agonist and antagonist use with PD risk in nationwide Danish health registries. RESULTS: We included 2,790 patients with PD and 11,160 controls. Long-term β2AR agonist use was associated with reduced PD risk (OR 0.57, 95% confidence interval [CI] 0.40-0.82) in this cohort. Unexpectedly, short-term β2AR agonist use was equally associated (OR 0.64, 95% CI 0.42-0.98). Because β2AR agonists are prescribed mostly for chronic obstructive pulmonary disease (COPD), often caused by long-term nicotine abuse, we analyzed other markers of smoking. Diagnosis of COPD (OR 0.51, 95% CI 0.37-0.69) and use of inhaled corticosteroids (OR 0.78, 95% CI 0.59-1.02) or inhaled anticholinergics (OR 0.41, 95% CI 0.25-0.67) were also inversely associated with PD. Increased PD risk was not found for all β2AR antagonists but only for propranolol and metoprolol. Associations were markedly stronger for short-term than long-term use. CONCLUSION: We confirmed β2AR agonist use to be associated with reduced PD risk and β2AR antagonist use with increased PD risk. However, our data indicate the association of β2AR agonists to be indirectly mediated by smoking, which is repeatedly associated with reduced risk of PD. The association of β2AR antagonists indicates reverse causation, with PD symptoms triggering their prescription rather than β2AR antagonists causing PD. Thus, current epidemiologic data do not support a causal link between β2AR agonists and antagonists and PD risk.
引用
- Hopfner F, Wod M, Höglinger GU, et al. Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. Neurology. 2019. PMID: 31127070. doi:10.1212/WNL.0000000000007694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。